Related Experiment Video
Updated: Feb 11, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice
1University of Florida College of Pharmacy, Department of Pharmacy Practice, PO Box 100486, Gainesville, FL 32610, USA. zineh@cop.ufl.edu
Abstract:
HMG-CoA reductase inhibitors (statins) are widely prescribed and recommended as first-line therapy for most patients with hypercholesterolemia or established coronary heart disease. However, there is interpatient variability in lipid-lowering response to statins that is not explained by initial cholesterol levels and inadequate dosing alone. Genetic polymorphisms may contribute. This review discusses the potential contribution of polymorphisms in genes encoding proteins involved in drug metabolism and transport, cholesterol biosynthesis, lipid metabolism and others to lipid responses to statins.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Characteristics of Practical Op Amps
The ratio of differential gain to the common-mode gain is defined as the common-mode rejection ratio (CMRR). This ratio quantifies the ability of operational amplifiers (op-amps) to reject common-mode...
Theoretical Foundations of Nursing Practice
Theories provide a perspective to assess patients' conditions and organize data and methods. They also assist in analyzing and interpreting information. They represent a...
Equivalent Circuits for Practical Transformers
In a practical transformer, each winding exhibits resistance and leakage reactance. The...
Dipeptidyl Peptidase 4 Inhibitors
Antihypertensive Drugs: Direct Renin Inhibitors

